131I-MIBG (iobenguane I-131) therapy
High-dose radioactive MIBG delivers radiation from inside neuroblastoma cells that take up noradrenaline; used for relapsed disease and tested in upfront therapy.
Overview
Response rate ~30-40% in relapsed/refractory MIBG-avid neuroblastoma (NANT, COG studies), with myelosuppression requiring stem-cell support at ≥12 mCi/kg. COG ANBL1531 randomised 131I-MIBG added to induction (primary results pending 2026). Commercial Azedra (for pheochromocytoma) was discontinued in 2024, leaving compounding and academic supply.
PubChem holds the molecule with stable iodine; the products carry I-123 or I-131 at the same position.
Norepinephrine transporter uptake of radio-iodinated benzylguanidine; 131I beta emission (2 mm range).
- PSMA / SSTR-positive cell
1.131I-MIBG (iobenguane I-131) therapy binds its target on the cancer cell or is taken up by it.
- Route
- IV
- Schedule
- 12-18 mCi/kg single or tandem doses with autologous stem-cell support; thyroid blockade with potassium iodide
- Monitoring
- Radiation isolation, counts, thyroid function, secondary malignancy
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"131I-MIBG iobenguane I-131 therapy" OR ABSTRACT:"131I-MIBG iobenguane I-131 therapy") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 131I-MIBG (iobenguane I-131) therapy, not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentIobenguane I-131 (therapeutic)
Shares Iobenguane I-123 (cardiac use), Iobenguane I-123, Norepinephrine transporter (NET), MIBG imaging and 131I-MIBG therapy.
- Idea18F-MFBG PET replacing 123I-MIBG scintigraphy
Shares High-risk neuroblastoma, Norepinephrine transporter (NET), Neuroblastoma (paediatric), MIBG imaging and 131I-MIBG therapy.
- CompanyY-mAbs Therapeutics
Shares High-risk neuroblastoma, Neuroblastoma (paediatric), Iodine-131.
- AgentFluorodopa F-18
Shares Iobenguane I-123, Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL), Iodine-123.
- IndicationHereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Shares Norepinephrine transporter (NET), Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL), Radioligand therapy (beta emitters).
- CompanyPDRadiopharma
Shares Iobenguane I-123 (cardiac use), Iodine-123, Iodine-131.
- AgentTemozolomide
Shares High-risk neuroblastoma, Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- TrialOpen-Label Study of 18F-mFBG for Imaging Neuroblastoma
Shares Norepinephrine transporter (NET), Neuroblastoma (paediatric).